Growing older could bring a slower loss of the abilities that make life enjoyable. The next generation of longevity medicine aims to help people see clearly, move confidently and recover more readily well into later life. Research into senescent cells, inflammatory signals and cellular reprogramming is creating several routes toward that future. Early human studies are beginning to connect laboratory discoveries with patient outcomes.
ParallaxSee forecasts that by the end of 2035, at least one treatment targeting harmful cellular senescence, IL-11 signaling or partial cellular reprogramming will demonstrate a benefit on a prespecified primary clinical endpoint in a randomized human trial enrolling at least 100 adults, with the endpoint assessed after at least six months. House probability: 65%, a rounded editorial estimate. The qualifying benefit must concern function or age-related disease, giving the forecast a practical meaning: a treatment that helps patients retain an ability or reduces the severity of illness. Longer human survival is the further ambition, which will require longer follow-up to establish.
One encouraging signal arrived in October 2026. A double-blind randomized trial tested dasatinib plus quercetin in 31 adults with fibrotic metabolic dysfunction-associated steatohepatitis, an inflammatory liver disease. Fibrosis improved without worsening the underlying disease in 47% of treated participants, compared with 7% receiving placebo. Adverse events were more frequent with treatment. The 21-week study needs confirmation in larger, longer trials, but it provides a concrete reason to pursue the approach: researchers observed a change in diseased human tissue. The Nature Metabolism study brings senolytic research closer to a clinical test of value.
Senolytics aim to remove harmful senescent cells, which have stopped dividing and can release signals that sustain inflammation and tissue damage. Senescence also serves useful roles, including wound repair and tumor suppression, making selective treatment essential. Mayo's US11517572B2 patent, granted in December 2022, illustrates how this biology becomes a specific therapeutic proposal. Its claims concern a particular dasatinib-and-quercetin administration method for pulmonary fibrosis. The patent and the newer liver experiment address different uses, but both point toward treating identifiable diseases through senescence biology.
Inflammatory signaling offers another route. In a 2024 Nature study, an antibody blocking IL-11 improved several measures of metabolism, muscle function and frailty in old mice. Treatment beginning at 75 weeks of age increased median lifespan by 22.5% in males and 25% in females. The important translational question is whether blocking the same pathway can protect human tissues during aging. The mouse percentages establish a reason to investigate that question; they cannot supply an estimate of extra human years.
The National University of Singapore and Singapore Health Services developed an associated patent family. Their WO2022090509A1 application, published in May 2022, proposes IL-11 inhibition for frailty and several age-related conditions. It makes the potential benefits concrete: preserving muscle, improving resilience and reducing damaging changes in organs. The application and the mouse paper arise from related research, so they represent one developing scientific program rather than independent confirmation.
Cellular reprogramming offers a particularly ambitious possibility: helping an existing cell recover youthful patterns of activity while continuing to perform its normal job. A 2020 Nature experiment expressed three factors, OCT4, SOX2 and KLF4, in mouse retinal cells. Researchers reported improved vision in aged mice and a mouse model of glaucoma, alongside changes in gene activity and DNA methylation. Restoring function in an accessible organ such as the eye offers a clear way to test whether reprogramming can become useful medicine.
That route has reached human development. The registered ER-100 trial plans to enroll 18 adults with glaucoma or a form of optic nerve injury. Its main purpose is to evaluate safety and tolerability, with longer follow-up to monitor vision and health. The registry estimates primary completion in May 2027 and final completion in March 2032. Those are planned dates, and the small, nonrandomized study will not satisfy this article's forecast. Its importance is the transition to a setting where researchers can directly observe how people respond.
Patents reveal different ways to approach the delivery problem. Harvard's US12409207B2, granted in September 2025, includes claims for a syringe containing a gene-expression vector encoding the three reprogramming factors. Stanford's US20210010034A1 application, published in January 2021, describes transient messenger RNA expression intended to rejuvenate cells while retaining their identity. These are technical proposals for controlling what reaches a cell and how it responds. Safe control of reprogramming will be central to clinical progress.
Chemical reprogramming could broaden the options further. In a 2023 study of cultured human cells, researchers identified six chemical combinations that shifted gene-expression patterns toward a younger state. Harvard's WO2025006954A2 application, published in January 2025, proposes chemical combinations for rejuvenating cells, tissues or organs. A chemical treatment could eventually offer another way to influence these processes, provided its effects can be controlled safely in living tissues. The published cellular results establish an early research foundation for that possibility.
Researchers are also exploring whether engineered immune cells can perform lasting maintenance. A 2024 Nature Aging study used CAR T cells to recognize uPAR, a protein found on many senescent cells. Treatment improved glucose tolerance and exercise capacity in aged mice, and a single administration produced lasting effects in the experiments. Memorial Sloan Kettering's US20220098320A1 application describes the corresponding strategy of targeting senescent cells with engineered immune cells. Human development will need to establish sufficiently precise targeting and acceptable risks.
Regenerative medicine is supplying another encouraging bridge toward translation. In a Chinese-led Cell study published in 2025, researchers administered genetically modified human mesenchymal progenitor cells to aged macaques over 44 weeks. They reported improvements in brain structure, cognition and several other aging-related indicators. The recipients were monkeys, and the study did not establish longer survival. Its contribution is evidence that engineered cells can influence multiple aspects of aging in a primate, supporting further investigation of repair and regeneration. Some coauthors are employees of Altos Labs; independent replication will be especially useful as the approach develops.
Progress will depend on measuring benefits that matter to patients. A 2026 analysis of 51 intervention studies and 16 epigenetic clocks found that these biomarkers respond differently to treatments. Their relationship with long-term clinical improvement remains uncertain. Better clocks may help researchers design efficient trials, while measures of vision, mobility, cognition and disease progression establish whether a treatment delivers a useful result. Combining biological measurements with clinical outcomes could make the next generation of studies more informative.
There is substantial work ahead. A 60-person senolytic trial in postmenopausal women missed its primary bone-resorption endpoint. The 48-week PEARL rapamycin trial, with 114 completers, also found no significant improvement in its primary measure of visceral fat, although some secondary measures improved. These results show why each proposed benefit needs its own test. Small positive studies may fail to replicate, side effects may constrain exposure, and funding or recruitment may delay larger trials. Those obstacles account for much of the uncertainty in the 65% forecast.
The optimistic case rests on several plausible mechanisms already producing functional or disease-related findings, and on a nine-year window for larger human tests. The estimate combines judgments about completing eligible studies, obtaining a valid primary clinical benefit and publishing results that withstand scrutiny. It is not a measured historical success rate. Patents add information about technical development; their titles and grants do not establish efficacy. Success in the defined trial would provide a foundation for further development, with approval, affordability and routine access still requiring additional work.
A 2024 demographic analysis found that life-expectancy gains had slowed in several long-lived populations. Its conclusion left a consequential opening: substantially slowing biological aging could change that trajectory. Longevity medicine is investigating that opening through measurable interventions. If useful treatments emerge, the first benefits may be more ordinary and more valuable than spectacular age records: clearer sight, stronger movement, fewer years limited by disease and greater independence in later life.
The forecast will be assessed at 23:59:59 UTC on December 31, 2035. A qualifying peer-reviewed report must be published after October 8, 2026, concern one of the three specified mechanisms, enroll at least 100 adults in a randomized controlled trial and assess its qualifying primary endpoint at least six months after randomization. It must meet the trial's prespecified statistical success rule for function or clinically accepted measures of age-related disease. Animal experiments, patents, biological-clock changes alone and positive exploratory findings after a failed primary test do not count. The milestone is a treatment showing that a meaningful part of aging-related decline can be changed in people.